Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,381

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

1,381 results for “Androgens”

Learn how ShareScore rates datasets ↗
dryad36/100

Data from: Androgens predict parasitism in female meerkats: a new perspective on a classic trade-off

The immunocompetence handicap hypothesis posits that androgens in males can be a 'double-edged sword', actively promoting reproductive success, while also negatively impacting health. Because there can be both substantial androgen concentrations in females and significant androgenic variation among them, particularly in species portraying female social dominance over males or intense female–female competition, androgens might also play a role in mediating female health and fitness. We examined this hypothesis in the meerkat (Suricata suricatta), a cooperatively breeding, social carnivoran characterized by aggressively mediated female social dominance and extreme rank-related reproductive skew. Dominant females also have greater androgen concentrations and harbour greater parasite loads than their subordinate counterparts, but the relationship between concurrent androgen concentrations and parasite burdens is unknown. We found that a female's faecal androgen concentrations reliably predicted her concurrent state of endoparasitism irrespective of her social status: parasite species richness and infection by Spirurida nematodes, Oxynema suricattae, Pseudandrya suricattae and coccidia were greater with greater androgen concentrations. Based on gastrointestinal parasite burdens, females appear to experience the same trade-off in the costs and benefits of raised androgens as do the males of many species. This trade-off presumably represents a health cost of sexual selection operating in females.

opencc-zeroDec 2015View details →
dryad36/100

Crucial roles of the mesenchymal androgen receptor in Wolffian duct development

<p>Wolffian duct maintenance and differentiation is predominantly driven by the androgen action, which is mediated by the androgen receptor (AR). It is well established that the mesenchyme indicates the fate and differentiation of epithelial cells. However, in vivo developmental requirement of mesenchymal AR in Wolffian duct development is still undefined. By designing a mesenchyme-specific <em>Ar</em> knockout (AR<sup>cKO</sup>), we discovered that the loss of mesenchymal <em>Ar</em> led to the bilateral or unilateral degeneration of caudal Wolffian ducts and cystic formation at the cranial Wolffian ducts. Ex vivo culture of AR<sup>cKO</sup> Wolffian ducts invariably resulted in bilateral defects, suggesting that some factor(s) originating from surrounding tissues in vivo might promote Wolffian duct survival and growth even in the absence of mesenchymal <em>Ar</em>. Mechanistically, we found cell proliferation was significantly reduced in both epithelial and mesenchymal compartments; but cell apoptosis was not affected. Transcriptomic analysis by RNA-seq of E14.5 mesonephroi revealed 131 differentially expressed genes. Multiple downregulated genes (<em>Top2a, Wnt9b, Lama2 and Lamc2</em>) were associated with morphological and cellular changes in AR<sup>cKO </sup>male embryos (i.e. reduced cell proliferation and decreased number of epithelial cells). Mesenchymal differentiation into smooth muscle cells that are critical for morphogenesis was also impaired in AR<sup>cKO </sup>male embryos. Taken together, our results demonstrate the crucial roles of the mesenchymal AR in Wolffian duct maintenance and morphogenesis in mice.</p>

opencc-zeroDec 2023View details →
zenodo36/100

Decoding the Epigenetics and Chromatin Loop Dynamics of Androgen Receptor-Mediated Transcription

<p>This repository stores the datasets for the "Decoding the Dynamic Regulation and Chromatin Architecture of Androgen Receptor-mediated Gene Expression" paper.</p>

opencc-by-4.0Sep 2024View details →
zenodo36/100

Androgen and prolactin manipulation do not induce changes in gene expression in the telencephalon in parental male bluegill (Lepomis macrochirus) during parental care

<p>Transcriptome of the prosencephalon of 11-KT, prolactin and placebo implanted&nbsp;fish.</p>

opencc-by-4.0Feb 2023View details →
dryad36/100

Data from: Androgen-armoured amazons – reversed sex roles in coucals are associated with testosterone in females but not males

<p class="MsoNormal">In some species, sexual selection is stronger in females than males. In classically polyandrous birds, for instance, females compete for mating opportunities and males care for offspring. Sex steroids such as testosterone have been suggested to regulate the behaviours of 'role-reversed' females and males, but comparative studies did not find evidence for a role of testosterone in relation to sex roles. However, the large variability of hormone measurements across laboratories may prevent detecting subtle differences in hormone levels. To circumvent this caveat, I compared sex steroid concentrations of females and males of two closely related and cohabiting species with different mating systems, the classically polyandrous black coucal (<em>Centropus grillii</em>) and the monogamous white-browed coucal (<em>C. superciliosus</em>). Baseline and GnRH-induced testosterone concentrations  were twice as high in female black coucals than  female white-browed coucals, and the low pre-breeding progesterone concentrations of female black coucals were consistent with progesterone's modulatory role during agonistic interactions in this species. Baseline and GnRH-induced testosterone and progesterone concentrations did not differ between males of both species. This study provides first evidence that elevated testosterone is associated with sex-role reversed traits in females, whereas low levels of testosterone may not be necessary to facilitate sex-role reversal in males.</p>

opencc-zeroMar 2023View details →
ClinicalTrials.gov36/100

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

ClinicalTrials.gov study NCT00519285. IPD Sharing: Not stated. Countries: 31. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

ClinicalTrials.gov study NCT03507608. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

ClinicalTrials.gov study NCT02749903. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

ClinicalTrials.gov study NCT01091103. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer

ClinicalTrials.gov study NCT02175212. IPD Sharing: Not stated. Countries: 1. Publications: 20.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

ClinicalTrials.gov study NCT02987829. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

ClinicalTrials.gov study NCT00385580. IPD Sharing: Not stated. Countries: 3. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women

ClinicalTrials.gov study NCT01889199. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov study NCT00936390. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1

ClinicalTrials.gov study NCT02574910. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

ClinicalTrials.gov study NCT00630344. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

ClinicalTrials.gov study NCT00090545. IPD Sharing: NO. Countries: 1. Publications: 9.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Pro

ClinicalTrials.gov study NCT04191096. IPD Sharing: YES. Countries: 29. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

ClinicalTrials.gov study NCT00450619. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

ClinicalTrials.gov study NCT00272038. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record